The Next Biotech Winners After the Vaccine Bubble Burst (ATRX, INMB, DVAX, SAVA, ICPT, IMGN, IBB, MRK, AZN)

The Covid story is starting to change. And you can hear the popping sound in the vaccine space. The needle is “therapeutics”. The therapeutic route was thought to be tricky for this virus on the near-term time horizon, which fueled a massive tsunami into the vaccine stocks as large money managers thought they would be […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Signs a Licensing Deal with Merck & Co., Inc. (NYSE:MRK) Animal Health

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) completes a Definitive Agreement giving Merck & Co., Inc. (NYSE:MRK) Animal Health the rights to build up and distribute Aurinia’s patented nano-micellar cyclosporin ophthalmic solution (VOS) for treating dry eye disorders in dogs. In this agreement, the Aurinia will obtain an upfront payment and they could receive more recompense which will […]

Merck & Co., Inc. (NYSE:MRK) Falters Over Januvia Sales And Poor Q3 Results

Boston, MA 10/30/2013 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) shares take a tumble following the poor weak earnings the company posted for the third quarter of 2013. The company continues to be troubled by patent issues with key drugs, which was further complicated by currency flip-flops. Both of the above primary drivers for the company […]

Merck & Co., Inc. (NYSE:MRK) To Save $2.5 Billion In Restructuring, Good News To Investors

Boston, MA 10/22/2013 (wallstreetpr) – After a seemingly good rally through last week, Merck & Co., Inc. (NYSE:MRK) eventually succumbed to the volatility in the health care sector to close the week on Friday, October 18, down by 1.06% to settle at $46.61. The global health care company is now undergoing restructuring efforts to see if it […]

Is Merck & Co., Inc. (NYSE:MRK) Still A Good Buy?

Boston, MA 10/21/2013 (wallstreetpr) – Merck & Co., Inc. (NYSE:MRK) has been struggling in the first half of 2013 on account of expiration some of the drug patents. It has embarked on an extensive restructuring program aimed at reducing costs by $2.5 billion. These reductions will be visible in 2014 and 2015. Maximum benefits are expected […]

Major Drug Makers; Johnson & Johnson (JNJ) and Eli Lilly (LLY) Database Collaboration – JNJ, PFE, BMY, MRK, ABT

On Monday, current three major drug makers Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and Merck & Co., Inc. (NYSE:MRK) have decided to collaborate on a database that will assist speed up the investigational drug testing process. The firm will each contribute to a database, which will be made of doctors, hospitals and […]